PReS-FINAL-2075: Biologic response modifiers: usage and safety profile from a North Indian pediatric rheumatology centre

M Agarwal,S Sawhney,M Jariwala

doi:10.1186/1546-0096-11-s2-p87

M Agarwal, S Sawhney + Show 1 more

Open Access

https://doi.org/10.1186/1546-0096-11-s2-p87

Copy DOI

Abstract

Biologic Response modifiers (BRMs) are sparingly used in the Indian subcontinent for two main reasons: economic constraints and concern of infections. We have used BRMs since 2006, albeit with stringent screening.There is a dearth of detail re the use and safety of BRMs from this part of the world. This study was undertaken to add to the knowledge about the use of BRMs in children with rheumatic diseases.

Highlights

Biologic Response modifiers (BRMs) are sparingly used in the Indian subcontinent for two main reasons: economic constraints and concern of infections
All were negative for HIV, HbsAg & HCV antibodies·Chest X ray normal in104; 1 had previous endobronchialTB·Mantoux test positive in 4: evaluation confirmed latent TB
Follow up: Considering the exorbitant cost and the self paying nature for a majority of patients, BRMs were used as remission inducing agents

Summary

Introduction

PReS-FINAL-2075: Biologic response modifiers: usage and safety profile from a North Indian pediatric rheumatology centre Introduction Biologic Response modifiers (BRMs) are sparingly used in the Indian subcontinent for two main reasons: economic constraints and concern of infections. We have used BRMs since 2006, albeit with stringent screening.There is a dearth of detail re the use and safety of BRMs from this part of the world.

Objectives

Results

Conclusion